Solution of Engineered Cell mRNA Technology

Engineered immune cells are designed to more precisely and effectively target and kill cancer cells through gene editing and modification techniques. These engineered immune cells include those expressing antigen receptors to enhance the tumor-targeting and killing capabilities of immune cells, such as CAR-T, TCR-T, CAR-NK, and CAR-macrophages. They also involve enhancing the immune response activation of immune cells to become stronger and more specific, such as DC fusion with tumor antigen epitopes to effectively activate tumor-specific CD4+ and CD8+ cells.

Eno Biotech provides a complete solution from sequence construction and cell transfection to functional analysis, including immune-enhanced cap analogs, expression-enhanced UTRs, and poly A tails, to meet the customized engineering needs of different types of cells, thereby facilitating high-level scientific research and achievement output for customers.

case study:

Application Characteristic Analysis Key Capability Elements for Characteristics
mRNA-CAR-T, TCR-T, CAR-NK, CAR-Macrophages Construction of CAR and TCR Structures Providing different generations of CAR and TCR structures, including CDS sequences, UTR, and poly A optimization to enhance mRNA expression efficiency for better meeting scientific research needs.
Transfection of T, NK, and Macrophage Cells Offering specific LNP transfection methods for T, NK, and macrophage cells, as well as mRNA electroporation methods for T, NK, and macrophage cells to meet the requirements for in vitro and in vivo transfection of T, NK, and macrophage cells.
Functional Validation of CAR-T, TCR-T, CAR-NK, and CAR-Macrophage Cells Equipped with various luciferase reporter cells to meet diverse needs for in vitro and in vivo killing validation of CAR-T, TCR-T, CAR-NK, and CAR-macrophage cells.
mRNA-DC Vaccine Epitope screening Proprietary algorithms are available for screening and predicting antigen epitopes, meeting the diverse requirements of personalized and universal tumor vaccines
Culturing and transfection of DC cells Targeted LNPs for DC cells, along with efficient methods for inducing maturation and transfection of DCs (both human and murine) in vitro, are provided to meet the needs of both in vivo and in vitro DC cell transfection.
Functional validation of DC vaccine Various evaluation methods such as ELISOPOT and ICS are employed to assess the activation of T cells by DC vaccines.

Case Study: mRNA-CAR T Solution

CAR-T cell therapy has shown remarkable efficacy in treating hematologic malignancies. However, it may lead to severe side effects such as cytokine storms, which could be relatively risky for patients with chronic autoimmune diseases, although potentially manageable for late-stage cancer patients. Utilizing mRNA to express CAR structures circumvents this risk as mRNA does not integrate into the T cell genome and does not sustain expression. Clinical studies treating patients with myasthenia gravis using CARs targeting BCMA mRNA have demonstrated that mRNA-based CAR-T cell therapy can significantly alleviate symptoms in patients with myasthenia gravis persistently and with good tolerability1.